Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Original Article Publisher



Vosough M1 ; Nikfam S2 ; Torabi S1 ; Sadri B1 ; Amoli HA3 ; Basi A4 ; Niknejadi M5 ; Hosseinkhannazer N6 ; Hosseini SE1 ; Mardpour S1 ; Azimian V1 ; Jaroughi N1 ; Aghdami N1 ; Amirzehni HR2 Show All Authors
Authors
  1. Vosough M1
  2. Nikfam S2
  3. Torabi S1
  4. Sadri B1
  5. Amoli HA3
  6. Basi A4
  7. Niknejadi M5
  8. Hosseinkhannazer N6
  9. Hosseini SE1
  10. Mardpour S1
  11. Azimian V1
  12. Jaroughi N1
  13. Aghdami N1
  14. Amirzehni HR2
  15. Anushirvani A2
  16. Malekzadeh R2
  17. Baharvand H7, 8
  18. Mohamadnejad M2
Show Affiliations
Authors Affiliations
  1. 1. Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
  2. 2. Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Hematology Oncology, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Reproductive Imaging, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
  6. 6. Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  7. 7. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran
  8. 8. Department of Developmental Biology, School of Basic Sciences and Advanced Technologies in Biology, University of Science and Culture, Tehran, Iran

Source: Cell Journal Published:2022


Abstract

Objective: Perianal fistulas in Crohn’s disease (CD) are the main challenges in inflammatory bowel diseases (IBDs). Some of the fistulas are refractory to any therapeutic strategy. The aim of this study was to evaluate the therapeutic effects of mesenchymal stromal cells (MSCs) as a novel promising modality for the treatment of fistulizing CD. Materials and Methods: This case series clinical interventional study was conducted from 2014 to 2017 at Shariati Hospital, an IBD referral center in Tehran, Iran. Refractory adult patients with CD who had draining perianal fistulas were enrolled in this study. All patients were examined by a colorectal surgeon and the fistula imaging studies were performed by pelvic magnetic resonance imaging (MRI). After autologous bone marrow (BM) aspiration and MSCs isolation, the cells were cultured and passaged under current good manufacturing practice (cGMP) conditions. Four intra-fistula injections of cells, each containing 40×106 MSCs suspended in fibrin glue, were administered by an expert surgeon every 4 weeks. Procedure safety, feasibility and closure of the perianal fistulas at week 24 were assessed. Clinical examination and MRI findings were considered as the primary end points. Results: In total, 5 patients (2 males and 3 females) were enrolled in this study. No adverse events were observed during the six-month follow-up in these patients. Both the Crohn’s Disease Activity Index (CDAI) and Perianal Disease Activity Index (PDAI) scores decreased in all patients after cell injections and one patient achieved complete remission with closure of fistulas, discontinuation of fistula discharge, and closure of the external opening. Conclusion: Local injection of MSCs combined with fibrin glue is potentially a safe and effective therapeutic approach for complex perianal fistulas in patients with CD. © 2022 Royan Institute (ACECR). All rights reserved.
Related Docs
1. Advanced Regenerative Medicine Strategies for Treatment of Perianal Fistula in Crohn's Disease, Inflammatory Bowel Diseases (2022)
2. Novel Cell-Based Therapies in Inflammatory Bowel Diseases: The Established Concept, Promising Results, Human Cell (2021)
3. Safety and Efficacy of Injection of Human Placenta Mesenchymal Stem Cells Derived Exosomes for Treatment of Complex Perianal Fistula in Non-Crohn's Cases: Clinical Trial Phase I, Journal of Gastroenterology and Hepatology (Australia) (2023)
4. Novel Cell-Based Therapies in Hepatic Disorders, Journal of Mazandaran University of Medical Sciences (2020)
5. Shining the Light on Clinical Application of Mesenchymal Stem Cell Therapy in Autoimmune Diseases, Stem Cell Research and Therapy (2022)
6. Localized Administration of Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Refractory Perianal Fistula in Patients With Crohn's Disease: A Phase Ii Clinical Trial, Diseases of the Colon and Rectum (2024)
Experts (# of related papers)
View all Related Experts
Mohammad Reza Keramati (3)
Amir Keshvari (3)